Dear SoFi Stock fans, mark your calendars for January 30th


SoFi Technologies ( SOFI ), founded in 2011, has entered earnings season with investors clearly more cautious than enthusiastic. The stock has dropped below $30 and is now trading about 40.34% below its 52-week high.

The decline followed a predictable sequence. Management’s $1.5 billion capital raising reopened concerns about dilution just as early investors began locking in profits after a sharp rally. With valuations already high, the market chose discipline and took a step back rather than push prices higher.

But a narrow focus on stocks obscures the bigger picture. SoFi’s underlying business is still expanding. Product adoption is consistent, membership growth is robust, and engagement metrics show no sign of fatigue.

The notion is supported by investor behavior. Shares rose 4.9% when the company revealed its earnings schedule on Jan. 2, and gained an additional 6.6% in after-hours trading.

So let’s weigh in on what investors might do with SoFi stock after earnings, which will be released on Friday, January 30th, before the market opens.

Based in San Francisco, California, SoFi is a member-centric digital financial ecosystem rather than a single-product fintech. With a market capitalization of about $31.1 billion, it spans lending, banking technology, APIs, investment tools and cash management under one integrated platform.

Even so, the course of the actions has not been smooth. Over the past 52 weeks, SoFi shares gained nearly 58.33%. The force rose 20% over six months before falling 5.95% last month as valuation discipline returned.

www.barchart.com
www.barchart.com

SoFi stock now trades at 70.95 times forward adjusted earnings and 9.17 times sales. The multiples are well above industry averages, indicating a significant premium and leaving little room for error as expectations remain high.

On Oct. 28, 2025, SoFi delivered Q3 2025 earnings that sent its stock up 5.5% in a single trading session. Revenue rose 37.9% year-over-year (YOY) to $961.6 million, easily beating analysts’ estimates of $904.4 million. Adjusted EPS rose 120% from the year-ago quarter to $0.11, beating consensus expectations of $0.08.



Source link

  • Related Posts

    China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner

    China’s CSPC Pharmaceutical, AstraZeneca’s long-acting obesity drug partner Source link

    5E Advanced Materials prices $36 million public offering

    5E Advanced Materials prices $36 million public offering Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *